For research use only. Not for therapeutic Use.
Imatinib-d3 hydrochloride (CAS: 1134803-18-1), a premium pharmaceutical research compound designed for advanced oncology and kinase inhibitor studies. As a deuterated analog of Imatinib hydrochloride, it offers enhanced stability and improved pharmacokinetic properties. Imatinib-d3 hydrochloride is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for chronic myeloid leukemia (CML) and other cancers. Trusted by leading laboratories, Imatinib-d3 hydrochloride is your go-to solution for cutting-edge cancer research. Unlock new possibilities in cancer treatment with Imatinib-d3 hydrochloride, where innovation meets reliability.
| Catalog Number | S000164 |
| CAS Number | 1134803-18-1 |
| Molecular Formula | C29H28D3N7O |
| Purity | ≥95% |
| Target | Anti-infection |
| IUPAC Name | N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-[[4-(trideuteriomethyl)piperazin-1-yl]methyl]benzamide |
| InChI | InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)/i2D3 |
| InChIKey | KTUFNOKKBVMGRW-BMSJAHLVSA-N |
| SMILES | [2H]C([2H])([2H])N1CCN(CC1)CC2=CC=C(C=C2)C(=O)NC3=CC(=C(C=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Iqbal N, et al. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027. [3]. Coleman CM, et al, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90(19):8924‐8933. Published 2016 Sep 12. |
